Background: The Prognostic Lung Fibrosis Consortium (PROLIFIC) was formed to develop well-qualified assays suitable for use as prognostic biomarkers within the context of clinical trials for Idiopathic ...

Protein biomarkers increasingly play a vital role in advancing health research, driving drug development, and improving clinical outcomes. The close connection between protein biomarkers and human ...

Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide, owing in part to the often late stage at which it is diagnosed. Biomarker development for HCC aims to improve ...

Alzheimer’s disease is defined by a progressive accumulation of misfolded proteins and neuronal loss that often predates clinical symptoms by years. Biomarkers aim to detect pathological hallmarks ...

Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...

In a set of newly released presentations, officials from the US Food and Drug Administration (FDA) explain changes to the agency's biomarker qualification program and detail early opportunities for ...

Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...

BrainTale unveils partnerships with leading research centers in Europe and in the US to ultimately improve brain care through biomarkers development. By powering precision neurology, the company ...

A research team working at MedUni Vienna has demonstrated that a specific component of the immune system (PTX-3) remains at significantly higher levels in the blood of patients who have suffered from ...

Researchers from Critical Path Institute's ® (C-Path) Predictive Safety Testing Consortium have proposed glutamate dehydrogenase (GLDH) as a more liver-specific biomarker for detecting liver injury, ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

Growing demand for healthcare, increasingly complex conditions, and persistent workforce shortages are creating an urgent need for solutions that improve both the quality and affordability of care.